Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2032MR)

This product GTTS-WQ2032MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2032MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1427MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ1545MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ884MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ5687MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ14504MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ9247MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ11338MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ4132MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW